<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04817735</url>
  </required_header>
  <id_info>
    <org_study_id>PI-2021-01</org_study_id>
    <nct_id>NCT04817735</nct_id>
  </id_info>
  <brief_title>The CASPER Registry</brief_title>
  <official_title>Calcium Algorithm Sizing for bicusPid Aortic Valve Evaluation With Raphe: the CASPER Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pisa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pisa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CASPER study is a prospective, international, multicenter registry which aims to evaluate&#xD;
      the use of an algorithm for choosing the size of the prosthesis to be implanted in patients&#xD;
      with bicuspid aortic stenosis type I treated by TAVI with Evolut® Pro prostheses (23 -26-29)&#xD;
      and Evolut® R 34.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY DESIGN&#xD;
&#xD;
      This is an Investigator initiated, international, multicenter, prospective registry,&#xD;
      enrolling 100 consecutive BAV patients who will undergo TAVI with the Evolut R/Pro&#xD;
      (23-26-29)/Evolut R 34THV.&#xD;
&#xD;
      Enrollment will be without limitation for each center (competitive enrollment). The&#xD;
      indication for TAVI will be based on each local Heart Team decision. As per local&#xD;
      institution's regulatory policy, each patient will provide a written informed consent for the&#xD;
      TAVI procedure, anonymous data collection and analysis. Each center will use its own consent&#xD;
      template.&#xD;
&#xD;
      All data will be collected in an electronic clinical report form (eCRF).&#xD;
&#xD;
      STUDY POPULATION Population&#xD;
&#xD;
      All consecutive patients diagnosed with type 0 or type 1 bicuspid aortic valve stenosis or&#xD;
      steno-insufficiency disease, undergoing transcatheter aortic valve implantation, as per local&#xD;
      standard of care.&#xD;
&#xD;
      CASPER algorithm&#xD;
&#xD;
      The sizing of the THV will be performed according to the proposed algorithm.&#xD;
&#xD;
      First step (&quot;calcium impact&quot;): subtract 1 mm in patients with aortic calcium volume ≥300 mm3&#xD;
      (i.e. ≥ Class I); no subtraction in patients with aortic calcium volume &lt;300 mm3 (i.e. Class&#xD;
      0).&#xD;
&#xD;
      Second step (&quot;raphe impact&quot;): subtract 1 mm if the raphe length is ≥50% of the perimeter&#xD;
      derived mean annulus diameter Further 0.5 mm will be subtracted if a high burden of calcium&#xD;
      is distributed predominantly on the raphe site.&#xD;
&#xD;
      In case of bicuspid Type 0 the second step should be skipped.&#xD;
&#xD;
      Transcatheter Aortic Valve Implantation Procedure&#xD;
&#xD;
      TAVI will be performed according to the local standards of care. Balloon valvuloplastywill be&#xD;
      performed to prepare for TAVI deployment, at operator's discretion. Balloon size should not&#xD;
      exceed the minimal diameter of the aortic annulus at baseline.&#xD;
&#xD;
      TAVI deployment will be performed as the current best practices. All Centers will be&#xD;
      encouraged to implant THV according to the two cusp alignment technique. If necessary, post&#xD;
      dilatation will be performed, based on the final hemodynamics and aortic regurgitation&#xD;
      assessment. The postdilatation will be performed according to the calcium burden with a&#xD;
      balloon size diameter equal to the minor annulus diameter or to the mean diameter.&#xD;
&#xD;
      Post-procedural MSCT scan&#xD;
&#xD;
      The post-procedural MSCT scan must be performed between 2 and 30 days after the index&#xD;
      procedure.&#xD;
&#xD;
      Post implant measurements of THV dimensions (perimeter and area) will be obtained at inflow&#xD;
      level, raphe level, and stent waist level (defined as the smallest dimension observed at any&#xD;
      plane of the implanted prosthesis). If the raphe level corresponds to the stent waist level,&#xD;
      only one measurement will be reported.&#xD;
&#xD;
      Eccentricity index will be calculated for each level. Eccentricity will be defined as&#xD;
      1-(minimal diameter/maximal diameter) and will be calculated both at the inflow and at the&#xD;
      narrowest level.&#xD;
&#xD;
      The post-procedural raphe length (defined as the longest measurable dimension of the&#xD;
      structure) will be measured at the same level of pre-procedural MSCT. The ratio between the&#xD;
      pre and post-procedure raphe length will be calculated for the assessment of raphe&#xD;
      shortening.&#xD;
&#xD;
      Strut separation data will be acquired (maximal strut distance, mean strut distance, strut&#xD;
      eccentricity index, i.e. maximal-minimal strut separation). The stent strut spaces will be&#xD;
      measured separately at the inflow level, with the first stent strut defined as the strut&#xD;
      closest to the commissure between the non-coronary and right coronary sinuses. The subsequent&#xD;
      struts will be numbered clockwise in an ascending order (1-15 for the Evolut THV).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of the CASPER algorithm</measure>
    <time_frame>1 year</time_frame>
    <description>The objective of the study is to validate the CASPER algorithm in a prospective cohort using a self-expandable THV, in order to assess the safety and efficacy of bicuspid aortic valve sizing based on calcium burden and raphe length.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of the CASPER algorithm</measure>
    <time_frame>1 year</time_frame>
    <description>To assess valve performance in terms of prosthesis mismatch and valve dysfunction (clinical features), and post-procedural CT assessment of the prosthesis behavior.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Bicuspid Aortic Valve</condition>
  <arm_group>
    <arm_group_label>Cohort</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TAVI</intervention_name>
    <description>TAVI sizing with dedicated algorithm</description>
    <arm_group_label>Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years.&#xD;
&#xD;
          2. NYHA≥2 and/or syncope and/or angina.&#xD;
&#xD;
          3. Patient judged by the Heart Team as indicated for TAVI.&#xD;
&#xD;
          4. Anatomical suitability for transfemoral or any alternative access TAVI, based on MSCT&#xD;
             assessment and local expertise and preference.&#xD;
&#xD;
          5. Estimated life expectancy&gt;1 year.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt;18 years&#xD;
&#xD;
          2. Estimated life expectancy&lt;1 year&#xD;
&#xD;
          3. Pure aortic regurgitation.&#xD;
&#xD;
          4. LVEF&lt;20%&#xD;
&#xD;
          5. No baseline MSCT evaluation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anna Sonia Petronio, M.D.</last_name>
    <phone>+39050995326</phone>
    <email>as.petronio@gmail.com</email>
  </overall_contact>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pisa</investigator_affiliation>
    <investigator_full_name>Anna Sonia Petronio</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>TAVI</keyword>
  <keyword>MSCT</keyword>
  <keyword>Bicuspid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bicuspid Aortic Valve Disease</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

